Bizarre Patents
An aircraft having vertical takeoff and landing capability provided with at least first and second laterally extending paddle wheels rotatable on a central axis perpendicular to the longitudinal axis of the aircraft fuselage and between its nose and tail.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110193 | Methods for conditioning a subject for hematopoietic cell transplantation Allogeneic hematopoietic cell transplantation (HCT) is an effective therapy for treatment of hematological malignancies and various autoimmune conditions. However, HCT traditionally requires conditioning by total body irradiation and/or chemotherapy, both of which a... | 02/07/2012 |
| 8105599 | Composition and method for modulating dendritic cell-T cell interaction The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another ma... | 01/31/2012 |
| 7927596 | Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or ... | 04/19/2011 |
| 7927595 | Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one o... | 04/19/2011 |
| 7914790 | Human IgM antibody lysing activated lymphocytes under mediation by homologous complement A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to... | 03/29/2011 |
| 7892551 | Antibody kit for enumeration of CD4+ lymphocytes The invention provides a method of enumerating the number of cells of a cell type in a cell sample by (a) counting the white blood cells in the cell sample to obtain the white blood cell population of the sample; (b) determining the proportion or percentage of the c... | 02/22/2011 |
| 7875279 | Inactivation of genes of the MEP pathway The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes... | 01/25/2011 |
| 7833530 | Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lym... | 11/16/2010 |
| 7829096 | CD40L-specific monovalent polypeptides The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or ... | 11/09/2010 |
| 7744888 | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to... | 06/29/2010 |
| 7736649 | Methods of inhibiting human immunodeficiency virus infection through the administration of synergistic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitors This invention provides a composition which comprises an admixture of three compounds, wherein: (a) one compound is an antibody which binds to a CCR5 receptor; (b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope g... | 06/15/2010 |
| 7722874 | Methods for reducing T cell responsiveness to an autoantigen with anti-gp39 antibodies and antigen presenting cells Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates con... | 05/25/2010 |
| 7604800 | Anti-PSGL-1 antibodies Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated i... | 10/20/2009 |
| 7592007 | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an ... | 09/22/2009 |
| 7592006 | Composition comprising the LO-CD2a antibody The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated ... | 09/22/2009 |
| 7563443 | Monovalent anti-CD40L antibody polypeptides and compositions thereof The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or ... | 07/21/2009 |
| 7501124 | Methods of inducing T-cell non-responsiveness with anti-gp39 24-31 antibodies Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface wh... | 03/10/2009 |
| 7476385 | Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1 Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred... | 01/13/2009 |
| 7445781 | Anti-CD40CR MR1 antibody The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that ... | 11/04/2008 |
| 7438905 | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositi... | 10/21/2008 |
| 7422745 | Methods of treating cancer with αβ-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide ... | 09/09/2008 |
| 7422744 | Methods of treating cancer with alphavbeta3-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypepti... | 09/09/2008 |
| 7393532 | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to metho... | 07/01/2008 |
| 7387776 | Human monoclonal antibodies against CD30 Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by underg... | 06/17/2008 |
| 7378092 | Immunogenic compositions for induction of anti-tumor immunity The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: | 05/27/2008 |
| 7364734 | Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell de... | 04/29/2008 |
| 7332582 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-... | 02/19/2008 |
| 7332157 | Methods for human allografting A method of preparing a human recipient for a graft from a human which includes: inducing mixed chimerism in the recipient (e.g., by administering to the recipient irradiation or chemotherapy), administering thymic irradiation, administering an antibody that deplete... | 02/19/2008 |
| 7323171 | Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage... | 01/29/2008 |
| 7312320 | Neutralizing antibodies and methods of use thereof This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using t... | 12/25/2007 |
| 7311910 | Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fus... | 12/25/2007 |
| 7309489 | Mouse CD40 ligand-specific antibodies and hybridomas There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding r... | 12/18/2007 |
| 7291331 | Methods of treating OX40 medicated recall immune responses T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model... | 11/06/2007 |
| 7288638 | Fully human antibodies against human 4-1BB Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject compris... | 10/30/2007 |
| 7288251 | Antibodies to CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 10/30/2007 |
| 7273712 | Methods and compositions for detecting compounds that modulate inflammatory responses The present invention relates to compositions and methods for identification and development of compounds or therapeutic agents that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to methods ... | 09/25/2007 |
| 7273609 | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by admin... | 09/25/2007 |
| 7259247 | Anti-human T-cell costimulating polypeptide monoclonal antibodies A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the ... | 08/21/2007 |
| 7250167 | Method of treatment with anti-CD2 antibody LO-CD2b A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation ... | 07/31/2007 |
| 7247474 | Monoclonal antibody which specifically binds to but does not activate the CD8 cells This invention provides a method of isolating CD8+ cells which employs an antibody which specifically binds to CD8 molecules present on the surface of CD8+ cells but does not activate the CD8+ cells once bound. This invention also pr... | 07/24/2007 |
